PricewaterhouseCoopers Study: New Jersey Pharmaceutical Companies Lead in Drugs in Development
New Brunswick, NJ, February 26, 2001 — New Jersey’s pharmaceutical companies are developing approximately one-third of all new products and indications now in clinical trials and awaiting FDA approval. In addition, New Jersey-based pharmaceutical and medical technology companies are showing significant increases in employment and capital investment.
New Jersey Continued to Lead Nation in FDA’s New Drug Approvals in 2000
New Brunswick, NJ, January 18, 2001 — Nearly 40 per cent of the U.S. Food and Drug Administration (FDA) approvals for new medicines in 2000 were given to research-based pharmaceutical companies headquartered in New Jersey.
Merck Chairman Raymond Gilmartin to Serve as Chairman of HealthCare Institute of New Jersey
New Brunswick, NJ, July 18, 2000 — Raymond V. Gilmartin, Chairman, President and CEO of Merck & Co., Inc., has been named Chairman of the HealthCare Institute of New Jersey effective on July 1, 2000. Mr. Gilmartin will serve a two-year term as chairman of the Institute, an association for the research-based pharmaceutical and medical […]
HINJ Releases 3rd Economic Impact Report: Pharmaceutical and Medical Technology Industry Shows Continued Growth, Strong Contributions to State Economy
$10.3 billion total economic impact on state in 1998, up $1.8 billion from 1997 ‘Cure Corridor’ supports more than 140,000 jobs statewide Capital investment by Institute members totaled $1.2 billion in 1998 PricewaterhouseCoopers survey documents direct and indirect economic benefits New Brunswick, NJ, January 26, 2000 — Each New Jersey job in the pharmaceutical and […]
New Jersey Leads in Medical Research, According to FDA
New Brunswick, NJ, March 29, 1999 — Thirty-eight new medicines were approved by the Food and Drug Administration (FDA) in 1998, and 14 of those drugs were the result of research by New Jersey-based pharmaceutical companies. More than 160 patent approvals were given to medical technology companies from our state.
HealthCare Institute of New Jersey, UMDNJ to Sponsor Medical Research Symposium
New Brunswick, NJ, September 25, 1998 — The HealthCare Institute of New Jersey and the University of Medicine and Dentistry of New Jersey (UMDNJ) announced today they will jointly host a research symposium on Friday, December 11, at the UMDNJ Conference Center in New Brunswick.
Zenner and Gilmartin to Head HealthCare Institute of New Jersey Board of Trustees
New Brunswick, NJ, July 7, 1998 — The HealthCare Institute of New Jersey announced today that Patrick J. Zenner, President and Chief Executive Officer of Hoffmann-La Roche Inc., has been elected Chairman of the Institute’s Board of Trustees, and Raymond V. Gilmartin, President, Chairman, and Chief Executive Officer of Merck & Co., Inc., has been […]
HealthCare Institute of New Jersey Names Rebecca Perkins Communications Director
New Brunswick, NJ, June 4, 1998 — The HealthCare Institute of New Jersey (HINJ), has announced that Rebecca Perkins has been named Director of Communications.
HealthCare Institute of New Jersey Releases Economic Impact Report
Coopers & Lybrand Finds Strong Pharma and Medical Device Presence Bolsters New Jersey’s Economy New Brunswick, NJ, December 11, 1997 — New Jersey’s pharmaceutical and medical technology industry continued to expand in the state through its commitment of $1 billion in capital expenditures for 1998. That capital investment, targeted primarily to research and development expansion, […]
Pharmaceutical and Health-Care Products Companies Form HealthCare Institute of New Jersey, a New Trade Association
Pharmaceutical Research Day Honors Industry′s Contributions Trenton, NJ, May 12, 1997 — The HealthCare Institute of New Jersey (HINJ), a new organization of leading pharmaceutical and health-care product companies in the state, was officially launched today at ceremonies held at the State House in Trenton.